Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA™, as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: Results of a pilot study

BJU International

Volumn 109, Issue 12, 2012, Pages 1770-1775

  Lepor, Herbert ^a   Cheli, Carol D ^b   Thiel, Robert P ^c   Taneja, Samir S ^a   Laze, Juliana ^a   Chan, Dan W ^d   Sokoll, Lori J ^d   Mangold, Leslie ^d   Partin, Alan W ^d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Clinical Consulting   (United States)

^c THIEL Statistical Consultants   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biochemical recurrence; PSA; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; MALE; PILOT STUDY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84861580651     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10568.x     Document Type: Article

References (26)

1. Balk SP, Ko YJ, Bubley GJ,. Biology of prostate-specific antigen. J Clin Oncol 2003; 21: 383-91
2. Oesterling JE,. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-23
3. Catalona WJ, Smith DS, Ratliff TL, et al,. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
4. Brawer MK, Chetner MP, Beatie J, et al,. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841-5
5. Freedland SJ, Moul JW,. Prostate specific antigen recurrence after definitive therapy. J Urol 2007; 177: 1985-91
6. Godoy G, Tareen BU, Lepor H,. Does Benign Prostatic Tissue Contribute to Measurable PSA Levels After Radical Prostatectomy? Urology 2009; 74: 167-70
7. Diamandis EP,. Prostate-specific antigen: its usefulness in clinical medicine. Trends Endocrinol Metab 1998; 9: 310-6
8. Polascik TJ, Oesterling JE, Partin AW,. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 1999; 162: 293-306
9. Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG,. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology 1997; 50: 573-79
10. Ferguson RA, Yu HE, Kalyvas M, et al,. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996; 42: 675-84
11. Eisenberg ML, Davies BJ, Coopeeberg MR, Cowan JE,. Prognostic Implications of an Undetectable Ultrasensitive Prostate-Specific Antigen Level after Radical Prostatectomy. Eur Urol 2010; 57: 622-9
12. Doherty AP, Bower M, Smith GL, et al,. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000; 83: 1432-6
13. Shen S, Lepor H, Yaffee R, Taneja S,. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005; 173: 777-80
14. Hong SK, Park HZ, Lee WK, et al,. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy. Urology 2010; 76: 723-27
15. Rissin DM, Fournier DR, Piech T, et al,. Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range. Anal Chem 2011; 83: 2279-85
16. Rissin DM, Kan CW, Campbell TG, et al,. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010; 28: 595-9
17. Bock JL, Klee GG,. How Sensitive Is a Prostate-Specific Antigen Measurement? How Sensitive Does It Need to Be? Arch Pathol Lab Med 2004; 128: 341-43
18. D'Amico AV, Moul J, Carroll PR, et al,. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004; 172 (5 Pt 2): S42-6
19. Trock BJ, Han M, Freedland SJ, et al,. Prostate Cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-9
20. Stewart AJ, Scher HI, Chen MH, et al,. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005; 23: 6556-60
21. Lughezzani G, Brigantu A, Karakiewicz PI,. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010; 58: 687-700
22. Thompson IM, Tangen CM, Paradelo J, et al,. Adjuvant radiotherapy for pathological T3N0M0 prostate reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol 2009; 181: 956-62
23. Yu HE, Diamandis P, Wong P, et al,. Detection of Prostate cancer relapse with prostate specific antigen monitoring levels of 0.001 to.1 ug/L. J Urol 1997; 157: 913-8
24. Nakamura M, Hasumi H, Miyoshi Y, et al,. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol 2005; 12: 1050-4
25. Hong SK, Park HZ, Lee WK, et al,. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy. Urology 2010; 76: 723-7
26. Thaxton CS, Elghanianc R, Thomasa AD, et al,. Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci USA 2009; 106: 18437-42